Chou Chia-I, Shih Chia-Jen, Chen Yung-Tai, Ou Shuo-Ming, Yang Chih-Yu, Kuo Shu-Chen, Chu Dachen
From the Department of Otolaryngology-Head and Neck Surgery, Mackay Memorial Hospital (C-IC); School of Medicine, National Yang-Ming University, Taipei (C-JS, Y-TC, S-MO, C-YY, S-CK); Deran Clinic, Yilan (C-JS); Division of Nephrology, Department of Medicine, Taipei City Hospital, Heping, Fuyou Branch (Y-TC); Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei (S-MO, C-YY); National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County (S-CK): Division of Infectious Diseases, Taipei Veterans General Hospital (SC-K); Institute of Public Health and Community Medicine Research Center, National Yang-Ming University (DC); Department of Health Care Management, National Taipei University of Nursing and Health Sciences (DC); and Department of Neurosurgery, Taipei City Hospital, Taipei, Taiwan (DC).
Medicine (Baltimore). 2016 Mar;95(9):e2645. doi: 10.1097/MD.0000000000002645.
To investigate the association between the use of nonselective or cyclooxygenase (COX)-2-selective nonsteroidal antiinflammatory drugs (NSAIDs) and risk of acute kidney injury (AKI) in a general Asian population. We conducted an observational, nationwide, nested case-control cohort study using Taiwan's National Health Insurance Research Database between 2010 and 2012. AKI cases were defined as hospitalization with a principle diagnosis of AKI. Each case was matched to 4 randomly selected controls based on age, sex, and the month and year of cohort entry. Odds ratios (ORs) were used to demonstrate the association between hospitalization for AKI and current, recent, or past use of an oral NSAID. During the study period, we identified 6199 patients with AKI and 24,796 matched controls. Overall, current users (adjusted OR 2.73, 95% confidence interval [CI] 2.28-3.28) and recent users (adjusted OR 1.17, 95% CI 1.01-1.35) were associated with increased risk of hospitalization for AKI. The risk was also similar for nonselective NSAIDs. However, neither current nor recent use of COX-2 inhibitors was significantly associated with AKI events. Our study supported that the initiation of nonselective NSAIDs rather than COX-2 inhibitors is associated with an increased risk of AKI requiring hospitalization. Future randomized trials are needed to elucidate these findings.
为了研究在一般亚洲人群中使用非选择性或环氧化酶(COX)-2选择性非甾体抗炎药(NSAIDs)与急性肾损伤(AKI)风险之间的关联。我们在2010年至2012年期间利用台湾全民健康保险研究数据库进行了一项全国性的观察性巢式病例对照队列研究。AKI病例定义为以AKI为主诊断的住院病例。根据年龄、性别以及队列进入的月份和年份,将每个病例与4名随机选择的对照进行匹配。比值比(OR)用于证明AKI住院与当前、近期或过去使用口服NSAIDs之间的关联。在研究期间,我们确定了6199例AKI患者和24796名匹配对照。总体而言,当前使用者(调整后的OR为2.73,95%置信区间[CI]为2.28 - 3.28)和近期使用者(调整后的OR为1.17,95%CI为1.01 - 1.35)与AKI住院风险增加相关。非选择性NSAIDs的风险也类似。然而,当前或近期使用COX-2抑制剂均与AKI事件无显著关联。我们的研究支持,启动非选择性NSAIDs而非COX-2抑制剂与需要住院治疗的AKI风险增加相关。未来需要进行随机试验以阐明这些发现。